Summary
Walmart Inc. has announced a proposed settlement agreement to resolve certain shareholder derivative actions concerning allegations of inadequate oversight in the distribution and dispensing of prescription opioids. The settlement, subject to court approval, would result in insurance carriers paying Walmart $123 million, minus any approved attorneys' fees and litigation expenses. Additionally, Walmart would commit to maintaining specific corporate governance practices for at least five years. This development aims to conclude ongoing legal disputes and avoid further costly litigation, though the company explicitly denies any admission of liability or wrongdoing.
Key Highlights
- 1Walmart has reached a settlement agreement to resolve shareholder derivative lawsuits related to opioid distribution and dispensing.
- 2The proposed settlement involves a payment of $123 million from insurance carriers to Walmart, subject to court approval and deduction of legal fees.
- 3As part of the settlement, Walmart will commit to maintaining certain corporate governance practices for a minimum of five years.
- 4The settlement does not involve any admission of liability or wrongdoing by Walmart or its directors and officers.
- 5The company previously established a Special Litigation Committee to investigate the claims and negotiate a resolution.
- 6The settlement is subject to approval by the Delaware Court of Chancery.